|
GB0516619D0
|
|
Methods of treatment of neoplastic disease
|
|
GB0516617D0
|
|
EP2 Receptor antagonists
|
|
GB0516439D0
|
|
EP2 receptor agonists
|
|
WO2005097113A2
|
|
5-ht2b receptor antagonists
|
|
US2005256170A1
|
|
EP2 receptor agonists
|
|
GB0423468D0
|
|
Prostanoid TP receptor antagonists and uses thereof
|
|
WO2005016338A1
|
|
Use of 5-ht2b receptor antagonists for the treatment of congestive heart failure
|
|
GB0414571D0
|
|
Use of secretin-receptor ligands in methods of treatment
|
|
GB0408063D0
|
|
5-HT2B receptor antagonists
|
|
GB0408064D0
|
|
5-HT2B receptor antagonists
|
|
GB0408062D0
|
|
5-HT2B receptor antagonists
|
|
GB0403368D0
|
|
EP2 receptor modulators
|
|
KR20050097966A
|
|
Ep4 receptor antagonists
|
|
GB0329620D0
|
|
EP2 receptor agonists
|
|
GB0324269D0
|
|
EP4 receptor antagonists
|
|
GB0317346D0
|
|
5-ht2b receptor antagonists
|
|
GB0312122D0
|
|
Therapeutic method
|
|
US2003158240A1
|
|
Methods for the treatment of primary headache disorders using prostanoid EP4 receptor antagonists, and assays for agents for such treatment
|
|
WO03068227A1
|
|
5-ht2b receptor antagonists
|
|
GB0302094D0
|
|
EP4 receptor antagonists
|
